Elevated Placental Growth Factor at 11 to 13 weeks 6 days period of gestation as a predictor of Gestational diabetes mellitus

This study , titles “Elevated placental growth factor at 11-13 weeks

6 days period of gestation as a predictor of gestational diabetes

mellitus,” is a prospective observational cohort study conducted at a

tertiary care hospital, utilizing data collected over the Antenatal

period , starting from time of NT Scan till termination of pregnancy ,

of patients that fulfil the inclusion criteria . Data collected over the

antenatal period will include PlGF levels at the time of NT Scan and

aneuplaoidy screening ( part of regular ANC , done after 11

completed weeks but before 14 completed weeks , that is by 13

weeks 6 days of gestation) , OGTT/GCT levels ( part of ANC , done

between 24-28 weeks in regular clinical practice) , maternal details

such as GPLA score, anthropometric measurements ( 1 st trimester

BMI, height) collected in 1 st trimester at the time of NT scan /

Aneuploidy screening . Patients will be followed up after NT

scan/aneuploidy screening during regular ANC visits . OGTT values (

done as part of regular ANC visit between the POG 24-28 weeks) will

be recorded in a proforma and patient will be classified as GDM

(gestational diabetes mellitus) and non GDM based on the same

according to standard cut-offs used in regular practice. Subsequent

FBS/PPBS values ( part of routine ANC tests for GDM patients) will

be recorded in the same proforma. Data will be entered in machine

learning tool (Random forest ) to help in formulation of a model that

will help predict GDM development . Ethical approval will be

obtained , with all data anonymized to maintain confidentiality. The

study’s findings can help in providing a valuable early predictor of

GDM in pregnancy that could potentially decrease both maternal and

fetal morbidity and mortality risks.